Analyzing Harrow (NASDAQ:HROW) & TNF Pharmaceuticals (NASDAQ:TNFA)

Harrow (NASDAQ:HROW) and TNF Pharmaceuticals (NASDAQ:TNFA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership and analyst recommendations.

Analyst Ratings

This is a summary of recent ratings and price targets for Harrow and TNF Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harrow	1	2	8	0	2.64
TNF Pharmaceuticals	1	0	0	0	1.00

Harrow currently has a consensus price target of $69.43, indicating a potential upside of 62.29%. Given Harrow’s stronger consensus rating and higher possible upside, equities analysts plainly believe Harrow is more favorable than TNF Pharmaceuticals.

Institutional & Insider Ownership

72.8% of Harrow shares are owned by institutional investors. Comparatively, 9.6% of TNF Pharmaceuticals shares are owned by institutional investors. 12.8% of Harrow shares are owned by insiders. Comparatively, 0.5% of TNF Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Harrow and TNF Pharmaceuticals”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harrow	$272.30 million	5.86	-$5.14 million	($0.41)	-104.34
TNF Pharmaceuticals	N/A	N/A	-$23.36 million	($231.00)	-0.02

Harrow has higher revenue and earnings than TNF Pharmaceuticals. Harrow is trading at a lower price-to-earnings ratio than TNF Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Harrow has a beta of 0.28, suggesting that its stock price is 72% less volatile than the S&P 500. Comparatively, TNF Pharmaceuticals has a beta of 2.04, suggesting that its stock price is 104% more volatile than the S&P 500.

Profitability

This table compares Harrow and TNF Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Harrow	-5.57%	19.59%	2.26%
TNF Pharmaceuticals	N/A	-69.21%	-33.98%

Summary

Harrow beats TNF Pharmaceuticals on 10 of the 13 factors compared between the two stocks.

About Harrow

Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

About TNF Pharmaceuticals

TNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.